Dr. Jelena Umbrasiene | Cardiology | Best Researcher Award
Cardiology consensus | Lithuania
Dr. Jelena Umbrasiene is a highly accomplished cardiologist and clinical researcher whose career reflects a strong commitment to advancing cardiovascular medicine through patient care, scientific research, and academic contributions. She earned her medical degree, specialized as a cardiologist, and completed her doctoral studies at the Lithuanian University of Health Sciences, building a solid academic foundation in clinical medicine and cardiovascular science. Professionally, she has served as a cardiologist in leading medical centers and private practices across Lithuania, combining clinical practice with extensive involvement in international clinical trials where she has contributed as a sub-investigator across multiple therapeutic areas. Her research interests include atherosclerosis, heart failure, myocardial and pericardial diseases, hypertension, and cardio-oncology, with a focus on innovative diagnostic and therapeutic strategies. She is skilled in conducting Good Clinical Practice–compliant clinical research, designing patient-centered treatment approaches, and delivering scientific communication through publications and presentations. Her contributions to science are evidenced by more than one hundred publications and over seven hundred presentations to physicians, reflecting her dedication to knowledge dissemination. Dr. Umbrasiene has been recognized through memberships in prestigious organizations such as the European Society of Cardiology and national associations, affirming her leadership in the field. Her career demonstrates excellence in combining clinical expertise, academic achievement, and research innovation, positioning her as a valuable contributor to cardiovascular science and patient care.
Profile: Google scholar
Featured Publications
Vanagas, G., Umbrasienė, J., & Šlapikas, R. (2012). Effectiveness of telemedicine and distance learning applications for patients with chronic heart failure: A protocol for prospective parallel group non-randomised open label study. BMJ Open, 2(5), e001346. — Citations: 13
Umbrasienė, J., Babarskienė, R. M., & Venclovienė, J. (2012). Lipoproteins impact increasing cardiovascular mortality. In Lipoproteins: Role in Health and Diseases (pp. 173-196). — Citations: 6
Umbrasienė, J., Buivydaitė, K., & Vasiliauskas, D. (2007). Išeminės širdies ligos rizikos susirgti nustatymas skirtingais metodais [Determination of risk of ischemic heart disease using different methods]. Lietuvos bendrosios praktikos gydytojas, 11(12), 840-843. — Citations: 5
Desai, A. S., Karns, A. D., Badariene, J., Aswad, A., Neutel, J. M., Kazi, F., Park, W., … (2025). Add-on treatment with Zilebesiran for inadequately controlled hypertension: The KARDIA-2 randomized clinical trial. JAMA. — Citations: 4
Umbrasienė, J., Vanagas, G., & Venclovienė, J. (2015). Does treatment impact health outcomes for patients after acute coronary syndrome? International Journal of Environmental Research and Public Health, 12(6), … — Citations: 4
Umbrasienė, J., Jankauskienė, E., Kupstytė, N., Babarskienė, M. R., … (2010). Prognostication of long-term outcomes for patients with ischemic heart disease. Medicina, 46(10), 700. — Citations: 3